Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LY007
i
Other names:
LY 007, LY007, CD20 CAR-T cells, CD20 CAR-T cells therapy, LY-007
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
China Biotech Services
Drug class:
CD20-targeted CAR-T immunotherapy
Related drugs:
‹
LYL314 (2)
ADI-001 (1)
MB-106 (1)
JNJ-4496 (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
CAR-20/19-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART20 (0)
CBM-C20.1 (0)
CD19/CD20 CAR T-cells (0)
CD20-CART (0)
CD20-CD19 cCAR T cells (0)
ELC-301 (0)
JNJ-9530 (0)
KITE-363 (0)
LCAR-AIO (0)
MB-CART20.1 (0)
PBCAR 20A (0)
RG6540 (0)
TriCAR19.20.22 T cells (0)
U16 (0)
YTS101 (0)
autologous TriCAR T (0)
bbT369 (0)
UCART20x22 (0)
multi-CAR-T cell therapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
MB-CART2019.1 (0)
LYL314 (2)
ADI-001 (1)
MB-106 (1)
JNJ-4496 (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
CAR-20/19-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART20 (0)
CBM-C20.1 (0)
CD19/CD20 CAR T-cells (0)
CD20-CART (0)
CD20-CD19 cCAR T cells (0)
ELC-301 (0)
JNJ-9530 (0)
KITE-363 (0)
LCAR-AIO (0)
MB-CART20.1 (0)
PBCAR 20A (0)
RG6540 (0)
TriCAR19.20.22 T cells (0)
U16 (0)
YTS101 (0)
autologous TriCAR T (0)
bbT369 (0)
UCART20x22 (0)
multi-CAR-T cell therapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
MB-CART2019.1 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.